German biotechnology company MorphoSys AG (MPSYY.PK) said it has received a milestone payment from Novartis AG (NVS) in connection with the initiation of a clinical phase 1 trial with a novel HuCAL antibody. The antibody will be tested in the field of prevention of thrombosis.
from RTT - Biotech http://ift.tt/29k9qTi
via IFTTT
No comments:
Post a Comment